scholarly journals Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study

2016 ◽  
Vol Volume 10 ◽  
pp. 2461-2466 ◽  
Author(s):  
Yin Yuan Zheng ◽  
Cheng Wu Tang ◽  
Ming Zhu ◽  
Wen Ming Feng ◽  
Ying Bao
Keyword(s):  
Hepatocellular Carcinoma ◽  
Retrospective Study ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Transarterial Chemoembolization ◽  
Chinese Herbal ◽  
Unresectable Hepatocellular Carcinoma

scholarly journals Efficacy of Chinese Herbal Medicine in the Treatment of Moderate-Severe Painful Diabetic Peripheral Neuropathy: A Retrospective Study

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Yujiao Zheng ◽  
Fan Yang ◽  
Lin Han ◽  
Xiaowen Gou ◽  
Fengmei Lian ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Retrospective Study ◽  
Blood Glucose ◽  
Peripheral Neuropathy ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Diabetic Peripheral Neuropathy ◽  
Limb Pain ◽  
Chinese Herbal ◽  
Painful Diabetic Peripheral Neuropathy

Painful diabetic peripheral neuropathy (pDPN) is a debilitating complication of diabetes. The aim of this retrospective study was to investigate the effectiveness of a Chinese herbal medicine regimen—the modified Huangqi Guizhi Wuwu Decoction (HGWD)—in the treatment of moderate-severe pDPN. The primary objective was to estimate the improvement in neuropathic pain severity. The secondary objective was to assess the response of common symptoms to the treatment. The change in patients’ blood glucose level during the whole treatment was also evaluated. By searching through our medical records of all the diabetic patients from January 2006 to January 2012, we identified and enrolled 30 moderate and severe pDPN patients in the study, for whom the treatment of neuropathic pain by regular pharmacotherapies had failed. The modified HGWD treatment was administered orally twice a day for 6 months. The numerical rating scale (NRS) level at month 6 was 2.57±2.30, significantly improved compared with the baseline level of 6.03±1.83 (P<0.05). The amelioration of 3 common symptoms, namely, limb pain, limb numbness, and insomnia, was evident, and the major response of common symptoms at month 6 including limb pain, insomnia, and limb coldness was significantly increased compared with the results at month 3 (P<0.05). Moreover, 2-hour postprandial blood glucose (2hPG) level decreased from 10.77±1.29 mmol/L at baseline to 9.66±0.60 mmol/L at month 6 (P<0.05). No serious adverse events occurred throughout the treatment period. The modified HGWD was effective in the treatment of moderate and severe pDPN and can thus be offered as a new alternative treatment option for pDPN patients who failed to respond to regular pharmaceutical therapies.

Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma

2013 ◽  
Vol 149 (3) ◽  
pp. 601-612 ◽  
Author(s):  
Yangyang Hu ◽  
Shengpeng Wang ◽  
Xu Wu ◽  
Jinming Zhang ◽  
Ruie Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Therapy ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Chinese Herbal

scholarly journals Jiedu Granule Combined with Transcatheter Arterial Chemoembolization and Gamma Knife Radiosurgery in Treating Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Jianchu Wang ◽  
Jinhong Luo ◽  
Xiaolan Yin ◽  
Wei Huang ◽  
Huangming Cao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Herbal Medicine ◽  
Portal Vein ◽  
Chinese Herbal Medicine ◽  
Median Overall Survival ◽  
Gamma Knife Radiosurgery ◽  
Therapeutic Strategies ◽  
Chinese Herbal ◽  
Baseline Characteristics ◽  
Arterial Chemoembolization

Background. The potential advantages of Jiedu granule (a compound Chinese herbal medicine) combined therapeutic strategies compared with non-Jiedu granule therapeutic strategies for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unclear. Thus, the purpose of the study was to investigate the safety and efficacy of Jiedu granule for HCC with PVTT. Methods. We retrospectively reviewed the clinical data of 190 patients (94 for non-Jiedu and 96 for Jiedu) with HCC and PVTT from March 2012 to October 2016. Patients were followed up by outpatient examination and telephone till November 2018. Results. It was statistically insignificant between the two groups in baseline characteristics. Procedure-related adverse events (AEs) were observed and compared and most of them were not serious which were easily controlled or subsided naturally. No AE-induced death happened. The median overall survival (OS) rates in the single TACE plus GKR and Jiedu granule combined group were 11.3 months (95% CI: 9.168-13.435) and 15.8 months (95% CI: 13.244-18.339), respectively (p = 0.00047). Conclusions. Jiedu granule combined with TACE plus GKR is safe in HCC patients with PVTT and this Chinese herbal medicine is worthy to be promoted because of better prognosis which needs further research.

Sign in / Sign up

Export Citation Format

Share Document